InvestLog
ONCY Oncolytics Biotech Inc. logo

ONCY Oncolytics Biotech Inc.

Healthcare
$0.81+2.47%ClosedMarket Cap: $81.2M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

-24.46

P/S

0.00

EV/EBITDA

-3.39

DCF Value

$0.02

FCF Yield

-25.5%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

5132.0%

ROA

-428.4%

ROIC

-1067.7%

Financials

View All
PeriodRevenueNet IncomeEPS
Q1 null$0.00$-12.9M$—
Q4 null$0.00$-1.5M$—
FY null$0.00$-39.5M$—
Q3 null$0.00$-14.4M$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

3 Strong Buy2 Buy1 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2025-11-17

Trading Activity

Insider Trades

View All
Parsons James T.director
BuyFri Mar 13
Kelly Jareddirector, officer: Chief Executive Officer
BuyFri Mar 13
Seizinger Bernd R.director
BuyFri Feb 13
Pisano Waynedirector
BuyFri Feb 13
Look Kirkofficer: Chief Financial Officer
BuyFri Feb 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

CA

Exchange

—

Beta

1.03

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Peers

ATOS logoATOSCLNN logoCLNNCOYA logoCOYAIMMX logoIMMXMGNX logoMGNXSRZN logoSRZNTIL logoTILTVGN logoTVGNWHWK logoWHWKZNTL logoZNTL